# OnCo record immatics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/immatics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "immatics" ;
  schema:name "Immatics"@en ;
  schema:description "TCR-T company whose PRAME-directed anzu-cel (IMA203) is in the phase 3 SUPRAME trial in melanoma, with a launch targeted for 2027."@en ;
  schema:url <https://onco.cc/companies/immatics/>, <https://immatics.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.globenewswire.com/news-release/2026/08/18/3346680/0/en/immatics-announces-second-quarter-2026-financial-results-and-business-update.html> ;
  schema:addressCountry "DE" ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/tcr-t/> ;
  onco:drugs <https://onco.cc/drugs/ima203/> ;
  onco:trials <https://onco.cc/trials/nct05958121/>, <https://onco.cc/trials/nct03686124/> .